5-(4-氟苯基)-4-甲基-4H-1,2,4-噻唑-3-硫醇 | 138417-35-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 5-(4-氟苯基)-4-甲基-4H-1,2,4-噻唑-3-硫醇
• 英文名称: 5-(4-fluorophenyl)-4-methyl-2,4-dihydro-3H-1,2,4-triazole-3-thione
• 英文别名: 5-(4-fluorophenyl)-4-methyl-4H-1,2,4-triazole-3-thiol；3-(4-fluorophenyl)-4-methyl-1H-1,2,4-triazole-5-thione
• CAS: 138417-35-3
• 化学式: C₉H₈FN₃S
• mdl: MFCD01940414
• 分子量: 209.247
• InChiKey: APKMKRLELRQWEB-UHFFFAOYSA-N

物化性质

• 沸点：
  266.3±42.0 °C(Predicted)
• 密度：
  1.38±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  59.7
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2933990090
• 危险性防范说明：
  P233,P260,P261,P264,P271,P280,P302+P352,P304,P304+P340,P305+P351+P338,P312,P321,P332+P313,P337+P313,P340,P362,P403,P403+P233,P405,P501
• 危险性描述：
  H315,H319,H335
• 储存条件：
  室温

反应信息

• 作为反应物：
  描述：

  5-(4-氟苯基)-4-甲基-4H-1,2,4-噻唑-3-硫醇 在 sodium hydroxide 、 phosphate buffer 、 碳酸氢钠 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 反应 4.0h， 生成 benzhydryl (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[[5-(4-fluorophenyl)-4-methyl-1,2,4-triazol-3-yl]sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
  参考文献：
  名称：

  Synthesis and structure—activity relationship of C-3 substituted triazolylthiomethyl cephems

  摘要：

  A series of C-3 substituted triazolylthiomethyl cephems with an aminothiazolemethoxyiminoacetamido side chain at C-7 were synthesized and tested for antimicrobial activity against clinically-relevant isolates. The compound with 3-pyridyl at C-5 and methyl at N-4 of the triazole moiety exhibited good antibacterial activity against both Gram-positive and Gram-negative bacteria, with the exception of pseudomonas spp against which none of the derivatives exhibited favorable activity.

  DOI：

  10.1016/0223-5234(96)80367-9
• 作为产物：
  描述：

  4-氟苯甲酰肼 在 碳酸氢钠 作用下， 以 四氢呋喃 为溶剂， 反应 26.0h， 生成 5-(4-氟苯基)-4-甲基-4H-1,2,4-噻唑-3-硫醇
  参考文献：
  名称：

  Kane; Staeger; Dalton, Journal of Medicinal Chemistry, 1994, vol. 37, # 1, p. 125 - 132

  摘要：

  DOI：

文献信息

• Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
  申请人：Edwards Louise

  公开号：US20050272779A1

  公开（公告）日：2005-12-08

  The present invention relates to new compounds of formula I, to pharmaceutical formulations containing the compounds, and to the use of the compounds in the prevention and/or treatment of mGluR5 receptor-mediated disorders.

  本发明涉及公式I的新化合物，包含该化合物的药物配方，以及利用该化合物预防和/或治疗mGluR5受体介导的疾病的用途。
• Synthesis, Antifungal Activity, 3D-QSAR, and Molecular Docking Study of Novel Menthol-Derived 1,2,4-Triazole-thioether Compounds
  作者：Mei Huang、Wen-Gui Duan、Gui-Shan Lin、Bao-Yu Li

  DOI：10.3390/molecules26226948

  日期：——

  displayed antifungal activity of 90.5% and 83.8%, respectively, against Colleterichum orbicalare and Fusarium oxysporum f. sp. cucumerinum. Compounds 5m (R = o-I Ph) had inhibition rates of 88.6%, 80.0%, and 88.0%, respectively, against F.oxysporum f. sp. cucumerinu, Bipolaris maydis and C. orbiculare. Furthermore, compound 5b (R = o-CH3 Ph) showed the best and broad-spectrum antifungal activity against

  设计、合成了一系列含有1,2,4-三唑-硫醚部分的新型薄荷醇衍生物，对其进行结构表征并进行生物学评估，以探索更有效的基于天然产物的抗真菌剂。生物测定结果表明，部分目标化合物在50 μg/mL浓度下对受试真菌，特别是对梨轮纹孢菌表现出良好的抑制活性。化合物5b (R= o -CH 3 Ph)、5i (R= o -Cl Ph)、5v (R= m,p -OCH 3 Ph)和5x (R= α-呋喃基)的抑制率为93.3％，对P. piricola 的抑制效果分别为 79.4% 和 79.4% ，远优于阳性对照百菌清。化合物5v（R= m，p -OCH 3 Ph）和5g（R= o -Cl Ph）对花生尾孢和玉米赤霉的抑制率分别为82.4%和86.5% ，远优于市售杀菌剂百菌清。 。化合物5b (R = o -CH 3 Ph)对Colleterichum orbicalare和Fusarium oxysporum
• Compounds
  申请人：Arora Jalaj

  公开号：US20060122397A1

  公开（公告）日：2006-06-08

  The present invention relates to new compounds of formula I, a process for their preparation and new intermediates prepared therein, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.

  本发明涉及化合物I的新化合物，其制备过程和其中制备的新中间体，含有该化合物的制药配方以及在治疗中使用该化合物的用途。
• ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS
  申请人：Edwards Louise

  公开号：US20080045571A1

  公开（公告）日：2008-02-21

  The present invention relates to new compounds of formula I, to pharmaceutical formulations containing the compounds, and to the use of the compounds in the prevention and/or treatment of mGluR5 receptor-mediated disorders.

  本发明涉及公式I的新化合物，包括含有该化合物的制药配方，以及该化合物在预防和/或治疗mGluR5受体介导的疾病中的使用。
• Triazole Compounds Suitable for Treating Disorders that Respond to Modulation of the Dopamine D3 Receptor
  申请人：Unger Liliane

  公开号：US20080171751A1

  公开（公告）日：2008-07-17

  The invention relates to compounds of the formula I: wherein n is 1 or 2, Ar is a C-bound 1,2,4-triazol radical which carries a radical R 1 on the remaining carbon atom and a radical R 1a on one of the nitrogen atoms; R 1 is hydrogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 4 alkoxymethyl, fluorinated C 1 -C 6 alkyl, fluorinated C 3 -C 6 cycloalkyl, fluorinated C 1 -C 4 alkoxymethyl, or optionally substituted phenyl or 5- or 6-membered heteroaryl; R 1a is hydrogen or C 1 -C 4 alkyl; and R 2 is C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, fluorinated C 1 -C 6 alkyl or fluorinated C 3 -C 6 cycloalkyl; and to the physiologically tolerated acid addition salts of these compounds. The invention also relates to a pharmaceutical composition that comprises at least one triazole compound of the formula I and/or at least one physiologically tolerated acid addition salt thereof, and further to a method for treating disorders that respond beneficially to dopamine D 3 receptor antagonists or dopamine D 3 agonists, said method comprising administering an effective amount of at least one triazole compound or physiologically tolerated acid addition salt of the formula I to a subject in need thereof.

  该发明涉及公式I的化合物：其中n为1或2，Ar为C-结合的1,2,4-三唑基团，在剩余碳原子上携带基团R1，并在其中一个氮原子上携带基团R1a；R1为氢、C1-C6烷基、C3-C6环烷基、C1-C4烷氧甲基、氟化C1-C6烷基、氟化C3-C6环烷基、氟化C1-C4烷氧甲基或可选取代的苯基或5-或6-成员杂环基；R1a为氢或C1-C4烷基；R2为C1-C6烷基、C3-C6环烷基、氟化C1-C6烷基或氟化C3-C6环烷基；以及这些化合物的生理耐受性酸加盐物。该发明还涉及一种制备至少一种公式I的三唑化合物和/或至少一种生理耐受性酸加盐物的制药组合物，以及一种治疗对多巴胺D3受体拮抗剂或多巴胺D3激动剂有益反应的疾病的方法，该方法包括向需要治疗的受体中给予至少一种公式I的三唑化合物或生理耐受性酸加盐物的有效剂量。